Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2146-2152

  John, Alison E ^a   Luckett, Jeni C ^a   Tatler, Amanda L ^a   Awais, Ramla O ^a   Desai, Ami ^b   Habgood, Anthony ^a   Ludbrook, Steve ^c   Blanchard, Andy D ^c   Perkins, Alan C ^a   Jenkins, R Gisli ^a   Marshall, John F ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Fibrosis; Integrin v 6; SPECT CT

Indexed keywords

A20FMDV2 PEPTIDE; ALPHAVBETA6 INTEGRIN; ALPHAVBETA6 INTEGRIN BLOCKING ANTIBODY; BETA6 INTEGRIN; BLOCKING ANTIBODY; HYDROXYPROLINE; INDIUM 111; MESSENGER RNA; PENTETIC ACID; PEPTIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; INDIUM; INTEGRIN; TUMOR ANTIGEN; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BIOASSAY; C57BL MOUSE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FIBROSING ALVEOLITIS; GENETICS; LUNG; METABOLISM; MULTIMODAL IMAGING; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; SIGNAL TRANSDUCTION; FIBROSIS; INTEGRIN ΑVΒ6; SPECT/CT;

ANIMALS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; ENDPOINT DETERMINATION; IDIOPATHIC PULMONARY FIBROSIS; INDIUM RADIOISOTOPES; INTEGRINS; LUNG; MALE; MICE; MICE, INBRED C57BL; MULTIMODAL IMAGING; PEPTIDES; PROGNOSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

FIBROSIS; INTEGRIN ΑVΒ6; SPECT/CT;

EID: 84893386130     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.120592     Document Type: Article

References (46)

1. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980-985.
2. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66:462-467.
3. Vancheri C. Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology. Proc Am Thorac Soc. 2012;9:153-157.
4. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229-2242.
5. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377: 1760-1769.
6. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431-440.
7. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
8. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208: 1339-1350.
9. Meyer KC. The natural history and diagnosis of idiopathic pulmonary fibrosis: are we all on the same page? Chest. 2011;140:3-4.
10. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185:1044-1048.
11. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531-537.
12. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:543-548.
13. Shin KM, Lee KS, Chung MP, et al. Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study. Radiology. 2008;249:328-337.
14. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med. 2008;177:433-439.
15. Kaufmann M, Pusztai L. Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an International Expert Panel. Cancer. 2011;117:1575-1582.
16. Alexandraki KI, Kaltsas G. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine. 2012;41:40-52.
17. Ellison DW. Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol. 2010;120:305-316.
18. Lee SH, Shim HS, Cho SH, et al. Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:102-112.
19. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184:92-99.
20. Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2012;18:441-446.
21. Ambrosini V, Zompatori M, De Luca F, et al. 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med. 2010;51:1950-1955.
22. Win T, Lambrou T, Hutton BF, et al. 18F-fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. Eur J Nucl Med Mol Imaging. 2012;39: 521-528.
23. Groves AM, Win T, Screaton NJ, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med. 2009;50:538-545.
24. Borie R, Fabre A, Prost F, et al. Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax. 2008;63:251-258.
25. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96:319-328.
26. Puthawala K, Hadjiangelis N, Jacoby SC, et al. Inhibition of integrin alpha(v) beta6, an activator of latent transforming growth factor-beta, prevents radiationinduced lung fibrosis. Am J Respir Crit Care Med. 2008;177:82-90.
27. Xu MY, Porte J, Knox AJ, et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol. 2009;174:1264-1279.
28. Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177:56-65.
29. Hausner SH, DiCara D, Marik J, Marshall JF, Sutcliffe JL. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. Cancer Res. 2007;67:7833-7840.
30. Hausner SH, Abbey CK, Bold RJ, et al. Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res. 2009;69:5843-5850.
31. Saha A, Ellison D, Thomas GJ, et al. High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6. J Pathol. 2010;222: 52-63.
32. Card JW, Carey MA, Bradbury JA, et al. Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J Immunol. 2006; 177:621-630.
33. Johnson KA. Imaging techniques for small animal imaging models of pulmonary disease: micro-CT. Toxicol Pathol. 2007;35:59-64.
34. Tatler AL, John AE, Jolly L, et al. Integrin alphavbeta5-mediated TGF-beta activation by airway smooth muscle cells in asthma. J Immunol. 2011;187:6094-6107.
35. Hahm K, Lukashev ME, Luo Y, et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol. 2007;170:110-125.
36. Wang B, Dolinski BM, Kikuchi N, et al. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology. 2007;46:1404-1412.
37. Popov Y, Patsenker E, Stickel F, et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol. 2008;48:453-464.
38. Koth LL, Alex B, Hawgood S, et al. Integrin beta6 mediates phospholipid and collectin homeostasis by activation of latent TGF-beta1. Am J Respir Cell Mol Biol. 2007;37:651-659.
39. Wang A, Yokosaki Y, Ferrando R, Balmes J, Sheppard D. Differential regulation of airway epithelial integrins by growth factors. Am J Respir Cell Mol Biol. 1996;15:664-672.
40. Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem. 1993; 41:1521-1527.
41. Larjava H, Koivisto L, Hakkinen L, Heino J. Epithelial integrins with special reference to oral epithelia. J Dent Res. 2011;90:1367-1376.
42. Huang XZ, Wu JF, Cass D, et al. Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin. J Cell Biol. 1996;133:921-928.
43. Häkkinen L, Koivisto L, Gardner H, et al. Increased expression of beta6-integrin in skin leads to spontaneous development of chronic wounds. Am J Pathol. 2004;164:229-242.
44. Utz JP, Ryu JH, Douglas WW, et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J. 2001;17:175-179.
45. Committee HPAGBAoRSA. Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and the Use of Sealed Radioactive Sources. Chilton, Didcot, Oxfordshire, U.K.: Health Protection Agency; 2006.
46. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992;33:652-658.